vg-3927 - Search News

Vigil Neuroscience shares rise on positive Alzheimer's trial data

Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease (AD).

Business Insider · 3d

Vigil Neuroscience reports data from Phase 1 trial on VG-3927

Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of

Seeking Alpha · 3d

Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)

Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 into a Phase 2 trial in Q3. Read more here.

Investing.com on MSN · 3d

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial

WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 clinical trial slated for the third quarter of 2025.

Business Insider · 3d

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral

BioSpace3d

Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.

FierceBiotech3d

Analysts 'highly encouraged' by TREM2 reduction seen in Vigil's phase 1 Alzheimer's data

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...

Taiwan News17d

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results